Artivion, Inc. (NYSE:AORT) Receives $32.00 Consensus Target Price from Brokerages

Artivion, Inc. (NYSE:AORTGet Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $32.00.

A number of equities analysts recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Artivion in a research report on Tuesday, June 17th. They set a “buy” rating and a $35.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Finally, Citizens Jmp raised shares of Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th.

View Our Latest Stock Analysis on AORT

Artivion Stock Performance

Shares of AORT stock opened at $31.17 on Thursday. The company has a fifty day moving average price of $27.99 and a two-hundred day moving average price of $27.51. The company has a debt-to-equity ratio of 1.08, a current ratio of 5.53 and a quick ratio of 3.95. The stock has a market cap of $1.33 billion, a P/E ratio of -62.34 and a beta of 1.62. Artivion has a one year low of $21.97 and a one year high of $32.33.

Artivion (NYSE:AORTGet Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). The company had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. As a group, equities analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Activity

In related news, SVP Marshall S. Stanton sold 10,548 shares of Artivion stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $29.13, for a total transaction of $307,263.24. Following the sale, the senior vice president now directly owns 105,332 shares in the company, valued at $3,068,321.16. This trade represents a 9.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 9,926 shares of Artivion stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total transaction of $287,854.00. Following the sale, the senior vice president now owns 187,258 shares in the company, valued at approximately $5,430,482. This represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,954 shares of company stock worth $2,108,525. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently added to or reduced their stakes in AORT. Legacy Advisors LLC acquired a new stake in Artivion during the 1st quarter worth approximately $28,000. MCF Advisors LLC lifted its position in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion in the 4th quarter worth approximately $64,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Artivion in the 4th quarter worth approximately $194,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

(Get Free Report

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Further Reading

Analyst Recommendations for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.